Loading...
EIGR.Q logo

Eiger BioPharmaceuticals, Inc.OTCPK:EIGR.Q Voorraadrapport

Marktkapitalisatie US$12.6m
Prijs aandeel
n/a
Mijn reële waarde
n.v.t.
1Y-5.6%
7D0%
1D
Portefeuillewaarde
​
Bekijk

Eiger BioPharmaceuticals, Inc.

OTCPK:EIGR.Q Voorraadrapport

Marktkapitalisatie: US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals (EIGR.Q) Aandelenoverzicht

Eiger BioPharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van therapieën voor hepatitis delta virus (HDV) en andere ernstige ziekten. Meer informatie

EIGR.Q fundamentele analyse
Sneeuwvlok Score
Waardering2/6
Toekomstige groei0/6
Prestaties in het verleden0/6
Financiële gezondheid0/6
Dividenden0/6

Risicoanalyse

Negatief eigen vermogen

De winst is de afgelopen 5 jaar met 9.7% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $13M )

Volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt


EIGR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Eiger BioPharmaceuticals, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Eiger BioPharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoersUS$8.50
52 Week HoogtepuntUS$16.00
52 Week LaagUS$1.10
Bèta2.78
1 maand verandering-15.00%
3 maanden verandering-24.11%
1 Jaar Verandering-5.59%
3 jaar verandering-95.66%
5 jaar verandering-97.13%
Verandering sinds IPO-98.22%

Recent nieuws en updates

Recent updates

Analyseartikel • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
Analyseartikel • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
Analyseartikel • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
Analyseartikel • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
Analyseartikel • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

Rendement voor aandeelhouders

EIGR.QUS BiotechsUS Markt
7D0%1.2%1.0%
1Y-5.6%34.9%28.7%

Rendement versus industrie: EIGR.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 34.9 % opleverde.

Rendement versus markt: EIGR.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.7 % opleverde.

Prijsvolatiliteit

Is EIGR.Q's price volatile compared to industry and market?
EIGR.Q volatility
EIGR.Q Average Weekly Movement12.9%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: De aandelenkoers van EIGR.Q is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van EIGR.Q is het afgelopen jaar gedaald van 39% naar 13%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
n/a25David Apelianwww.eigerbio.com

Eiger BioPharmaceuticals, Inc., een biofarmaceutisch bedrijf in een commerciële fase, richt zich op de ontwikkeling van therapieën voor hepatitis delta virus (HDV) en andere ernstige ziekten. Het bedrijf biedt Zokinvy aan voor de behandeling van het Hutchinson-Gilford progeriesyndroom en Processing-Deficient Progeroid Laminopathies. De productkandidaten omvatten Lonafarnib, een oraal beschikbare farnesylatieremmer, die klinische studies in Fase 3 voor HDV-infectie heeft voltooid; Peginterferon Lambda (lambda), dat in klinische ontwikkeling is voor HDV; lambda, dat zich in onderzoeksstudies in Fase II en III bevindt voor milde en matige COVID-19; en Avexitide, dat zich in Fase II bevindt voor de behandeling van congenitaal hyperinsulinisme en post-bariatrische hypoglykemie.

Eiger BioPharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Eiger BioPharmaceuticals zich tot de beurswaarde?
EIGR.Q fundamentele statistieken
MarktkapitalisatieUS$12.59m
Inkomsten(TTM)-US$74.96m
Inkomsten(TTM)US$15.77m
0.8x
P/S-verhouding
-0.2x
Koers/Winstverhouding

Is EIGR.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EIGR.Q resultatenrekening (TTM)
InkomstenUS$15.77m
Kosten van inkomstenUS$24.00k
BrutowinstUS$15.75m
Overige uitgavenUS$90.71m
Inkomsten-US$74.96m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-50.62
Brutomarge99.85%
Nettowinstmarge-475.26%
Schuld/Eigen Vermogen Verhouding-284.4%

Hoe presteerde EIGR.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/10/02 09:05
Aandelenkoers aan het einde van de dag2024/10/01 00:00
Inkomsten2023/12/31
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Eiger BioPharmaceuticals, Inc. wordt gevolgd door 11 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.